These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19590255)

  • 1. p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy.
    Faget DV; Luo X; Inkman MJ; Ren Q; Su X; Ding K; Waters MR; Raut GK; Pandey G; Dodhiawala PB; Ramalho-Oliveira R; Ye J; Cole T; Murali B; Zheleznyak A; Shokeen M; Weiss KR; Monahan JB; DeSelm CJ; Lee AV; Oesterreich S; Weilbaecher KN; Zhang J; DeNardo DG; Stewart SA
    Cancer Discov; 2023 Jun; 13(6):1454-1477. PubMed ID: 36883955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis.
    Gordon D; Kivitz A; Singhal A; Burt D; Bangs MC; Huff EE; Hope HR; Monahan JB
    ACR Open Rheumatol; 2023 Feb; 5(2):63-70. PubMed ID: 36604812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis.
    Guenthoer P; Fuchs K; Reischl G; Quintanilla-Martinez L; Gonzalez-Menendez I; Laufer S; Pichler BJ; Kneilling M
    Inflammopharmacology; 2019 Dec; 27(6):1217-1227. PubMed ID: 31037574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.
    Murali B; Ren Q; Luo X; Faget DV; Wang C; Johnson RM; Gruosso T; Flanagan KC; Fu Y; Leahy K; Alspach E; Su X; Ross MH; Burnette B; Weilbaecher KN; Park M; Mbalaviele G; Monahan JB; Stewart SA
    Cancer Res; 2018 Oct; 78(19):5618-5630. PubMed ID: 30093561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals.
    Wang C; Hockerman S; Jacobsen EJ; Alippe Y; Selness SR; Hope HR; Hirsch JL; Mnich SJ; Saabye MJ; Hood WF; Bonar SL; Abu-Amer Y; Haimovich A; Hoffman HM; Monahan JB; Mbalaviele G
    J Exp Med; 2018 May; 215(5):1315-1325. PubMed ID: 29549113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p38 MAPK inhibits nonsense-mediated RNA decay in response to persistent DNA damage in noncycling cells.
    Nickless A; Cheruiyot A; Flanagan KC; Piwnica-Worms D; Stewart SA; You Z
    J Biol Chem; 2017 Sep; 292(37):15266-15276. PubMed ID: 28765281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of cytokine production by glucocorticoids is mediated by MKP-1 in human lung epithelial cells.
    Keränen T; Moilanen E; Korhonen R
    Inflamm Res; 2017 May; 66(5):441-449. PubMed ID: 28299397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Inflammatory Effects of β2-Receptor Agonists Salbutamol and Terbutaline Are Mediated by MKP-1.
    Keränen T; Hömmö T; Hämäläinen M; Moilanen E; Korhonen R
    PLoS One; 2016; 11(2):e0148144. PubMed ID: 26849227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p38MAPK plays a crucial role in stromal-mediated tumorigenesis.
    Alspach E; Flanagan KC; Luo X; Ruhland MK; Huang H; Pazolli E; Donlin MJ; Marsh T; Piwnica-Worms D; Monahan J; Novack DV; McAllister SS; Stewart SA
    Cancer Discov; 2014 Jun; 4(6):716-29. PubMed ID: 24670723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual specificity phosphatase 1 regulates human inducible nitric oxide synthase expression by p38 MAP kinase.
    Turpeinen T; Nieminen R; Taimi V; Heittola T; Sareila O; Clark AR; Moilanen E; Korhonen R
    Mediators Inflamm; 2011; 2011():127587. PubMed ID: 21547253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis.
    Peterson JD; Labranche TP; Vasquez KO; Kossodo S; Melton M; Rader R; Listello JT; Abrams MA; Misko TP
    Arthritis Res Ther; 2010; 12(3):R105. PubMed ID: 20509880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function.
    Du Y; Tang J; Li G; Berti-Mattera L; Lee CA; Bartkowski D; Gale D; Monahan J; Niesman MR; Alton G; Kern TS
    Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2158-64. PubMed ID: 20071676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.
    Mourey RJ; Burnette BL; Brustkern SJ; Daniels JS; Hirsch JL; Hood WF; Meyers MJ; Mnich SJ; Pierce BS; Saabye MJ; Schindler JF; South SA; Webb EG; Zhang J; Anderson DR
    J Pharmacol Exp Ther; 2010 Jun; 333(3):797-807. PubMed ID: 20237073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha.
    Mihara K; Almansa C; Smeets RL; Loomans EE; Dulos J; Vink PM; Rooseboom M; Kreutzer H; Cavalcanti F; Boots AM; Nelissen RL
    Br J Pharmacol; 2008 May; 154(1):153-64. PubMed ID: 18297096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p38 MAP kinase inhibitors: many are made, but few are chosen.
    Dominguez C; Powers DA; Tamayo N
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):421-30. PubMed ID: 16022178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel strategies for inhibition of the p38 MAPK pathway.
    Zhang J; Shen B; Lin A
    Trends Pharmacol Sci; 2007 Jun; 28(6):286-95. PubMed ID: 17482683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SD0006: a potent, selective and orally available inhibitor of p38 kinase.
    Burnette BL; Selness S; Devraj R; Jungbluth G; Kurumbail R; Stillwell L; Anderson G; Mnich S; Hirsch J; Compton R; De Ciechi P; Hope H; Hepperle M; Keith RH; Naing W; Shieh H; Portanova J; Zhang Y; Zhang J; Leimgruber RM; Monahan J
    Pharmacology; 2009; 84(1):42-60. PubMed ID: 19590255
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.